Pharsight

1. List of Retevmo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112942	LOXO ONCOLOGY INC	Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors	Oct, 2037 (14 years from now)
US10584124	LOXO ONCOLOGY INC	Crystalline forms	Oct, 2038 (15 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137124	LOXO ONCOLOGY INC	Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors	Oct, 2037 (14 years from now)
US10172851	LOXO ONCOLOGY INC	Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors	Oct, 2037 (14 years from now)
US10786489	LOXO ONCOLOGY INC	Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile	Oct, 2038 (15 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 8, 2025
Orphan Drug Exclusivity (ODE)	May 8, 2027

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 2024-05-08

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treatment of adult patients with...

Dosage: CAPSULE;ORAL